Author

Sarah Ossing

Observed name: S. Ossing

Institution: Dana-Farber Cancer Institute

Observed institution: Dana-Farber Cancer Institute

OpenAlex ID: A5117723614

DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease.

2025 · Paolo Tarantino, Tianyu Li, et al. · Journal of Clinical Oncology · 2

Abstract PS1-09-02: Intracranial activity of datopotamab deruxtecan (Dato-DXd) for patients with HER2-negative breast cancer and leptomeningeal disease (LMD): Results from Cohort C of the DATO-BASE phase 2 trial

2026 · P. Tarantino, N. Zhou, et al. · Clinical Cancer Research · 1

A single-arm, phase II study of sequential therapy with curative intent in de novo HER2+ metastatic breast cancer: The SAPPHO study.

2026 · Stefania Morganti, Kathryn Jean Ruddy, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 3

H-index: 1

I10-index: